Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | BUB1 | O43683 | 3/20 | 0.48 |
| ▸ | GRM5 | P41594 | 3/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3636023 | 0.88 | MAPT (0.56) | MAPK1POLBMAPTGRM5CSNK2A1 | |
| SCHEMBL4514156 | 0.88 | MAPT (0.70) | MAPK1POLBMAPTGRM5MEN1 | |
| SCHEMBL3633584 | 0.86 | MAPT (0.58) | MAPK1POLBMAPTGRM5MEN1 | |
| SCHEMBL3636750 | 0.85 | SMARCA2 (0.47) | BUB1GRM5CSNK2A1MEN1KMT2A | |
| SCHEMBL3629063 | 0.82 | GRM5 (0.65) | MAPK1POLBMAPTGRM5 | |
| SCHEMBL4221699 | 0.75 | P2RY12 (0.57) | GRM5MEN1KMT2AP2RY12 | |
| SCHEMBL2813594 | 0.74 | MAPK1 (0.44) | MAPK1POLBMAPTGRM5MEN1 | |
| SCHEMBL26436181 | 0.74 | MAPK1 (0.53) | MAPK1MAPTGRM5MEN1KMT2A | |
| SCHEMBL4514060 | 0.73 | GRM5 (0.57) | MAPK1POLBMAPTGRM5MEN1 | |
| SCHEMBL15706876 | 0.73 | MAPK1 (0.46) | MAPK1POLBMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679299-A | Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5 | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| EP-2146969-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20090105266-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| WO-2008128968-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | NOVARTIS AG (CH) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105266-A1 | Organic compounds | SLCO2B1, SLCO1B1, SLCO1B3 | MAPK1 2649/4885POLB 1030/4885MAPT 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.